![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif)
cefpodoxime proxetil A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) | cefpodoxime | | ![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) | Vantin | | ![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081024120512im_/http://www.cancer.gov/images/spacer.gif) |